Verition Fund Management
PSTX

Verition Fund Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Verition Fund Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,673
Closed -$31.2K – 3577
2024
Q2 		$31.2K Buy
+10,673
New +$29.2K ﹤0.01% 2837
2023
Q2 		– Sell
-47,579
Closed -$147K – 2622
2023
Q1 		$147K Buy
47,579
+34,079
+252% +$204K ﹤0.01% 1845
2022
Q4 		$71.5K Buy
+13,500
New +$61.7K ﹤0.01% 1869

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Verition Fund Management's PSTX Position: Q3 2024 in Review

Verition Fund Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q3 2024, closing a stake of 10,673 shares — an estimated $31.2K sold.

Verition Fund Management first reported a position in PSTX in Q4 2022 and held it in 3 quarters. The position peaked at $147K in Q1 2023. 96 funds tracked by Wall St. Rank hold PSTX as of Q3 2024.

  • Verition Fund Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Verition Fund Management sold 10,673 Poseida Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $31.2K.
  • Verition Fund Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • Verition Fund Management's Poseida Therapeutics, Inc. Common Stock position peaked at $147K in Q1 2023.
  • 96 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Verition Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.